341 related articles for article (PubMed ID: 31800076)
21. Treatment of Abnormalities of Potassium Homeostasis in CKD.
Palmer BF; Clegg DJ
Adv Chronic Kidney Dis; 2017 Sep; 24(5):319-324. PubMed ID: 29031359
[TBL] [Abstract][Full Text] [Related]
22. The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease.
Tamargo J; Caballero R; Delpón E
Expert Opin Pharmacother; 2021 Jul; 22(10):1319-1341. PubMed ID: 33620275
[No Abstract] [Full Text] [Related]
23. [What's new in hyperkalemia management?].
Lefevre F; Mousseaux C; Bobot M
Rev Med Interne; 2024 Jun; 45(6):350-353. PubMed ID: 38220492
[TBL] [Abstract][Full Text] [Related]
24. Management of Chronic Hyperkalemia in Patients With Chronic Kidney Disease: An Old Problem With News Options.
Morales E; Cravedi P; Manrique J
Front Med (Lausanne); 2021; 8():653634. PubMed ID: 34150795
[TBL] [Abstract][Full Text] [Related]
25. Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy.
Sampani E; Theodorakopoulou M; Iatridi F; Sarafidis P
Expert Opin Pharmacother; 2023; 24(16):1775-1789. PubMed ID: 37545002
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.
Beccari MV; Meaney CJ
Core Evid; 2017; 12():11-24. PubMed ID: 28356904
[TBL] [Abstract][Full Text] [Related]
27. Updates on medical management of hyperkalemia.
Lopes MB; Rocha PN; Pecoits-Filho R
Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):417-423. PubMed ID: 31268919
[TBL] [Abstract][Full Text] [Related]
28. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
Henneman A; Guirguis E; Grace Y; Patel D; Shah B
Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
[TBL] [Abstract][Full Text] [Related]
29. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
Valdivielso JM; Balafa O; Ekart R; Ferro CJ; Mallamaci F; Mark PB; Rossignol P; Sarafidis P; Del Vecchio L; Ortiz A
Drugs; 2021 Sep; 81(13):1467-1489. PubMed ID: 34313978
[TBL] [Abstract][Full Text] [Related]
30. Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors.
De Nicola L; Ferraro PM; Montagnani A; Pontremoli R; Dentali F; Sesti G
Intern Emerg Med; 2024 Mar; 19(2):295-306. PubMed ID: 37775712
[TBL] [Abstract][Full Text] [Related]
31. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of potassium binders in the treatment of patients with chronic kidney disease and hyperkalemia.
Dong L; Xu W; Deng Y; Tan J; Qin W
Eur J Pharmacol; 2022 Sep; 931():175174. PubMed ID: 35964658
[TBL] [Abstract][Full Text] [Related]
33. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
Minà C; Ajello L; Gesaro GD; Falletta C; Clemenza F
Rev Cardiovasc Med; 2020 Jun; 21(2):241-252. PubMed ID: 32706212
[TBL] [Abstract][Full Text] [Related]
34. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
35. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
36. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
Obi Y; Thomas F; Dashputre AA; Goedecke P; Kovesdy CP
Kidney Med; 2024 Jan; 6(1):100757. PubMed ID: 38192434
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
Kuijvenhoven MA; Haak EA; Gombert-Handoko KB; Crul M
Int J Clin Pharm; 2013 Dec; 35(6):1099-104. PubMed ID: 23974985
[TBL] [Abstract][Full Text] [Related]
38. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
39. Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors.
Fravel MA; Meaney CJ; Noureddine L
Curr Hypertens Rep; 2023 Nov; 25(11):395-404. PubMed ID: 37747576
[TBL] [Abstract][Full Text] [Related]
40. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
